RxDoctor Payments DataLook up a doctor →

Bruce Cohen, MD

Neurology · Chicago, ILNPI 1174553580

Payments from drug & device makers

$501,101in general payments, 2019–2025

Across 172 payments — averaging $2913.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$205K
  • Sanofi$71K
  • Sanofi-aventis U.S. LLC$70K
  • Sanofi US Services Inc.$64K
  • AstraZeneca$20K
  • Mylan Specialty L.p.$15K
  • plus $57K from 12 others
$2,184in research payments, 2019–2025

Across 2 payments — averaging $1092.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$259,99194%
  • Speaking & faculty fees$11,1174%
  • Travel & lodging$3,2191%
  • Food & beverage$2,0611%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$501,101 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,420,123
Medicare patients
186
Services billed
104,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate30$334,203
CopaxoneGlatiramer Acetate32$229,994
GilenyaFingolimod Hcl13$124,894
Avonex Pen (4 Pack)Interferon Beta-1a15$120,936
Avonex (4 Pack)Interferon Beta-1a15$120,784
Glatiramer Acetate30$51,076
Dalfampridine ErDalfampridine67$28,463
Dimethyl Fumarate24$6,081
RivastigmineRivastigmine Tartrate18$3,604
Baclofen114$2,677
FingolimodFingolimod Hcl11$2,332
Gabapentin85$2,227
ValacyclovirValacyclovir Hcl17$909
Pregabalin27$786
Tizanidine Hcl28$776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack)$9,624$454,98645 claims
NovartisGilenya$2,423$124,89413 claims
Mylan Institutional Inc.Glatiramer Acetate$6,930$51,07630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →